Stock Financial Ratios

LJPC / La Jolla Pharmaceutical Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)748.05
Enterprise Value ($M)457.87
Book Value ($M)61.04
Book Value / Share3.54
Price / Book6.24
NCAV ($M)61.04
NCAV / Share3.54
Price / NCAV6.35
Income Statement (mra) ($M)
Net Income-78.19
Balance Sheet (mrq) ($M)
Cash & Equivalents120.84
Cash / Share7.01
Quick Ratio6.91
Current Ratio6.91
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.28
Return on Assets (ROA)-1.10
Return on Equity (ROE)-1.28
Identifiers and Descriptors
Central Index Key (CIK)920465
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)22.15
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Additional Paid In Capital Per Share46.21
Inventory Work In Progress Per Share0.00
Assets Current Per Share7.17
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Property Plant And Equipment Per Share0.38
Cash Per Share7.01
Liabilities Current Per Share0.60
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Liabilities Per Share0.60
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Liabilities And Stock Equity Per Share7.55
Property Plant And Equipment Net Per Share0.38
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Cash And Equivalents Per Share7.01
Retained Earnings Per Share-39.64
Assets Per Share7.55
Equity Per Share6.95

Related News Stories

PRO Weekly Digest: Special Situation, Distressed And Event-Driven Investing With Value Detective

2017-11-19 seekingalpha
How to find special situation and event-driven opportunities, merger arb and distressed investing are topics discussed and Value Detective shares a bullish thesis on PICO Holdings and Cision. (24-0)

La Jolla: Red Flags And A Vastly Overestimated Market Create A Compelling Short

2017-11-16 seekingalpha
The market potential for La Jolla's primary asset, a treatment for hypo-tension in Septic Shock patients, is severely overestimated in my opinion. (250-1)

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

2017-10-28 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

2017-10-10 reuters
* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [] Further company coverage: (7-2)

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

2017-09-25 reuters
* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage: (2-1)

CUSIP: 503459604